High Prescription Rate of Medications With Rifampin Drug–drug Interactions in Patients With Diabetic Foot Osteomyelitis: Should Rifabutin Be Included in Clinical Trials for Adjunctive Therapy?
Rifampin may improve diabetic foot osteomyelitis outcomes, but its extensive drug-drug interactions could hamper its use. Here, through a review of the medications prescribed to a cohort of 190 persons with diabetic foot osteomyelitis, we show that rifabutin, a rifamycin with fewer drug-drug interactions, would be easier to implement in practice.
Authors
- Christina Mallarino-Haeger (ORCID: https://orcid.org/0000-0001-5212-7730)
- Marcos C. Schechter (ORCID: https://orcid.org/0000-0002-6165-7423)
- Muaaz Choudhary
- Russell Ryan Kempker (ORCID: https://orcid.org/0000-0002-7188-4996)
- Maya Fayfman (ORCID: https://orcid.org/0000-0002-8733-3160)
- Umnia Mahgoub (ORCID: https://orcid.org/0000-0002-8482-8504)
- Lily Francis (ORCID: https://orcid.org/0000-0002-5460-8279)
- Manish B. Patel (ORCID: https://orcid.org/0000-0003-1372-9696)
- Maryam Heydari (ORCID: https://orcid.org/0009-0007-3379-4846)
- Allison Watson (ORCID: https://orcid.org/0000-0003-2207-9971)
- Manuel Garcia-Toca
Institutions
- Emory University (US)
- Augusta University (US)
- Grady Health System (US)
- Temple University (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1093/ofid/ofae582
- Citations
- 2
- Primary Topic
- Diabetic Foot Ulcer Assessment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.72
Funders
- Emory University